

**Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222)
against SARS-CoV-2 BA.4/BA.5 and XBB sublineages**

SUPPLEMENTARY APPENDIX

Authors: Bradley K. Ackerson¹, Katia J. Bruxvoort^{1,3}, Lei Qian¹, Lina S. Sy¹, Sijia Qiu¹, Julia E. Tubert¹, Gina S. Lee¹, Jennifer H. Ku¹, Ana Florea¹, Yi Luo¹, Radha Bathala¹, Julie Stern¹, Soon K. Choi¹, Harpreet S. Takhar¹, Michael Aragonés¹, Morgan A. Marks⁴, Evan J. Anderson⁴, Cindy Ke Zhou⁴, Tianyu Sun⁴, Carla A. Talarico^{4,5}, Hung Fu Tseng^{1,2}

Affiliations:

1. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
2. Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA
3. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA
4. Moderna Inc., Cambridge, MA, USA
5. AstraZeneca, Gaithersburg, MD, USA

Corresponding author:

Bradley Ackerson, MD, Department of Research and Evaluation, Kaiser Permanente Southern California. 100 S. Los Robles Ave, 2nd Floor. Pasadena, CA 91101.

Tel: 424-328-2202, Email: Bradley.K.Ackerson@kp.org

ORCID: 0000-0002-0816-7345

Alternative corresponding author:

Hung Fu Tseng, PHD, Department of Research and Evaluation, Kaiser Permanente Southern California. 100 S. Los Robles Ave, 2nd Floor. Pasadena, CA 91101.

Tel: 626-564-3451, Email: Hung-Fu.X.Tseng@kp.org

ORCID: 0000-0001-6184-6534

Contents

Supplementary Table 1. Characteristics of SARS-CoV-2 specimens, by sequencing status and vaccination status.....	5
Supplementary Table 2. Characteristics of SARS-CoV-2 test-positive cases and test-negative controls with mRNA-1273 bivalent vaccine or unvaccinated.....	6
Supplementary Table 3. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥ 2 monovalent mRNA vaccines against infection and severe outcomes with SARS-CoV-2 variants by time since vaccination.....	9
Supplementary Table 4. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against infection and severe outcomes with SARS-CoV-2 variants by time since vaccination	11
Supplementary Table 5. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥ 2 monovalent mRNA vaccines against infection and severe outcomes with SARS-CoV-2 variants by age group.....	13
Supplementary Table 6. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against infection and severe outcomes with SARS-CoV-2 variants by age group	15
Supplementary Table 7. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥ 2 monovalent mRNA vaccines against infection and severe outcomes with SARS-CoV-2 variants among immunocompromised patients.....	17
Supplementary Table 8. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against infection and severe outcomes with SARS-CoV-2 variants among immunocompromised patients	18
Supplementary Table 9. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥ 2 monovalent mRNA vaccines against infection and severe outcomes with SARS-CoV-2 variants among those with history of SARS-CoV-2 infection	19
Supplementary Table 10. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against infection and severe outcomes with SARS-CoV-2 variants among those with history of SARS-CoV-2 infection.....	20
Supplementary Table 11. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥ 2 monovalent mRNA vaccines against infection and severe outcomes with SARS-CoV-2 variants by time since vaccination, using SGTF data to assign unidentified subvariants.....	21
Supplementary Table 12. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against infection and severe outcomes with SARS-CoV-2 variants by time since vaccination, using SGTF data to assign unidentified subvariants	23
Supplementary Table 13. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥ 2 monovalent mRNA vaccines against infection and severe outcomes with XBB.1.5 subvariant	25
Supplementary Table 14. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against infection and severe outcomes with XBB.1.5 subvariant.....	26

Supplementary Table 15. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥ 2 monovalent mRNA vaccines against severe outcomes with SARS-CoV-2 variants among individuals without antiviral treatment.....27

Supplementary Table 16. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against severe outcomes with SARS-CoV-2 variants among individuals without antiviral treatment.....28

Supplementary Figure 1. Flow chart for Moderna bivalent vaccine test-negative design study population.....29

Supplementary Figure 2. Distribution of SARS-CoV-2 variants by vaccination status30

Supplementary Figure 3. Distribution of SARS-CoV-2 variants by month of specimen collection31

Supplementary Table 1. Characteristics of SARS-CoV-2 specimens, by sequencing status and vaccination status

	Sequencing Success				Sequencing Failure			
	mRNA-1273 bivalent vaccinated	≥2 doses monovalent mRNA	Unvaccinated	Total	mRNA-1273 bivalent vaccinated	≥2 doses monovalent mRNA	Unvaccinated	Total
Overall, n	1632	9946	3706	15284	1445	7945	3553	12943
Specimen type, n (%)								
Nasopharyngeal/oropharyngeal swab	1477 (90.5%)	9110 (91.6%)	3416 (92.2%)	14003 (91.6%)	1141 (79.0%)	6536 (82.3%)	2900 (81.6%)	10577 (81.7%)
Saliva	155 (9.5%)	836 (8.4%)	290 (7.8%)	1281 (8.4%)	304 (21.0%)	1409 (17.7%)	653 (18.4%)	2366 (18.3%)
Composite Ct value, n (%) ^a								
≤27	1607 (98.5%)	9731 (97.8%)	3619 (97.7%)	14957 (97.9%)	285 (19.7%)	1659 (20.9%)	651 (18.3%)	2595 (20.0%)
>27	25 (1.5%)	201 (2.0%)	82 (2.2%)	308 (2.0%)	916 (63.4%)	5058 (63.7%)	2202 (62.0%)	8176 (63.2%)
Missing	0 (0.0%)	14 (0.1%)	5 (0.1%)	19 (0.1%)	244 (16.9%)	1228 (15.5%)	700 (19.7%)	2172 (16.8%)
SGTF data available, n (%)	1212 (74.3%)	7349 (73.9%)	2440 (65.8%)	11001 (72.0%)	1121 (77.6%)	6360 (80.1%)	2740 (77.1%)	10221 (79.0%)
ED/UC encounters	590 (36.2%)	3374 (33.9%)	1444 (39.0%)	5408 (35.4%)	504 (34.9%)	2410 (30.3%)	1013 (28.5%)	3927 (30.3%)
COVID-19 hospitalization, n (%)	64 (3.9%)	427 (4.3%)	160 (4.3%)	651 (4.3%)	55 (3.8%)	258 (3.2%)	101 (2.8%)	414 (3.2%)
COVID-19 hospital death, n (%)	6 (0.4%)	26 (0.3%)	8 (0.2%)	40 (0.3%)	2 (0.1%)	10 (0.1%)	6 (0.2%)	18 (0.1%)
Variant, n (%)								
BA.2	72 (4.4%)	379 (3.8%)	136 (3.7%)	587 (3.8%)	N/A	N/A	N/A	N/A
BA.4	3 (0.2%)	157 (1.6%)	70 (1.9%)	230 (1.5%)	N/A	N/A	N/A	N/A
BA.5 (excluding BQ)	190 (11.6%)	3020 (30.4%)	1238 (33.4%)	4448 (29.1%)	N/A	N/A	N/A	N/A
BQ	558 (34.2%)	3363 (33.8%)	1338 (36.1%)	5259 (34.4%)	N/A	N/A	N/A	N/A
XBB.1.5	533 (32.7%)	2045 (20.6%)	655 (17.7%)	3233 (21.2%)	N/A	N/A	N/A	N/A
XBB.1.16	59 (3.6%)	167 (1.7%)	39 (1.1%)	265 (1.7%)	N/A	N/A	N/A	N/A
XBB.1.9	105 (6.4%)	297 (3.0%)	57 (1.5%)	459 (3.0%)	N/A	N/A	N/A	N/A
Other XBB (excluding XBB.1.5, XBB.1.16, XBB.1.9)	102 (6.3%)	472 (4.7%)	147 (4.0%)	721 (4.7%)	N/A	N/A	N/A	N/A
Other	10 (0.6%)	46 (0.5%)	26 (0.7%)	82 (0.5%)	N/A	N/A	N/A	N/A

SGTF = S gene target failure, ED/UC = emergency department/urgent care, N/A = not applicable

^a Cycle threshold (Ct) values from RT-qPCR performed at Helix OpCo, LLC, using a single signal for the combined S and N genes.

Supplementary Table 2. Characteristics of SARS-CoV-2 test-positive cases and test-negative controls with mRNA-1273 bivalent vaccine or unvaccinated

	Test Positive N=10336	Test Negative N=31008	p value	ASD
Age at specimen collection date, years			0.42	0.01
mean (sd)	40.46 (24.89)	40.16 (24.98)		
median	41	40		
Q1, Q3	21, 61	20, 61		
min, max	0.5, 103	0.5, 104		
Age at specimen collection date, years, n (%)			N/A	N/A
≤5	1270 (12.3%)	3810 (12.3%)		
6-17	1118 (10.8%)	3354 (10.8%)		
18-44	3322 (32.1%)	9966 (32.1%)		
45-64	2593 (25.1%)	7779 (25.1%)		
65-74	1119 (10.8%)	3357 (10.8%)		
≥75	914 (8.8%)	2742 (8.8%)		
Sex, n (%)			N/A	N/A
Female	5462 (52.8%)	16386 (52.8%)		
Male	4874 (47.2%)	14622 (47.2%)		
Race/Ethnicity, n (%)			N/A	N/A
Non-Hispanic White	2689 (26.0%)	8067 (26.0%)		
Non-Hispanic Black	1058 (10.2%)	3174 (10.2%)		
Hispanic	4944 (47.8%)	14832 (47.8%)		
Non-Hispanic Asian	1011 (9.8%)	3033 (9.8%)		
Other/Unknown	634 (6.1%)	1902 (6.1%)		
Body mass index ^a , kg/m ² , n (%)			<0.01	0.14
<18.5	1069 (10.3%)	3994 (12.9%)		
18.5 - <25	2134 (20.6%)	6577 (21.2%)		
25 - <30	2414 (23.4%)	7365 (23.8%)		
30 - <35	1712 (16.6%)	5320 (17.2%)		
35 - <40	874 (8.5%)	2657 (8.6%)		
40 - <45	381 (3.7%)	1108 (3.6%)		
≥45	249 (2.4%)	800 (2.6%)		
Unknown	1503 (14.5%)	3187 (10.3%)		
Smoking ^a , n (%)			<0.01	0.07
No	7835 (75.8%)	23471 (75.7%)		
Yes	1711 (16.6%)	5642 (18.2%)		
Unknown	790 (7.6%)	1895 (6.1%)		
Charlson comorbidity score ^{b,c}			<0.01	0.07
mean (sd)	0.80 (1.69)	0.92 (1.78)		
median	0	0		
Q1, Q3	0, 1	0, 1		
min, max	0, 14	0, 15		
Charlson comorbidity score ^{b,c} , n (%)			<0.01	0.09
0	7078 (68.5%)	19943 (64.3%)		
1	1541 (14.9%)	5076 (16.4%)		
≥2	1717 (16.6%)	5989 (19.3%)		

Frailty index ^{b,d}			<0.01	0.06
mean (sd)	0.12 (0.03)	0.12 (0.03)		
median	0.11	0.11		
Q1, Q3	0.10, 0.13	0.10, 0.13		
min, max	0.06, 0.39	0.05, 0.37		
Frailty index ^{b,d} , n (%)			<0.01	0.08
Quartile 1	2597 (25.1%)	7741 (25.0%)		
Quartile 2	2821 (27.3%)	7513 (24.2%)		
Quartile 3	2505 (24.2%)	7832 (25.3%)		
Quartile 4, most frail	2413 (23.3%)	7922 (25.5%)		
Chronic diseases ^b , n (%)				
Kidney disease	630 (6.1%)	2063 (6.7%)	0.05	0.02
Heart disease	394 (3.8%)	1454 (4.7%)	<0.01	0.04
Lung disease	1251 (12.1%)	4509 (14.5%)	<0.01	0.07
Liver disease	392 (3.8%)	1401 (4.5%)	<0.01	0.04
Diabetes	1330 (12.9%)	4255 (13.7%)	0.03	0.03
Immunocompromised, n (%)			<0.01	0.04
Yes	421 (4.1%)	1521 (4.9%)		
HIV/AIDS	23	98		
Leukemia, lymphoma, congenital and other immunodeficiencies, asplenia/hyposplenia	176	518		
Organ transplant	49	119		
Immunosuppressant medications	272	1031		
Autoimmune conditions ^b , n (%)			0.94	<0.01
Yes	336 (3.3%)	1013 (3.3%)		
Rheumatoid arthritis	140	451		
Inflammatory bowel disease	65	234		
Psoriasis and psoriatic arthritis	123	313		
Multiple sclerosis	25	47		
Systemic lupus erythematosus	32	102		
Pregnant at specimen collection date, n (%)			<0.01	0.16
Yes	198 (1.9%)	1453 (4.7%)		
1st trimester	28	100		
2nd trimester	53	129		
3rd trimester	117	1224		
History of SARS-CoV-2 infection ^e , n (%)			<0.01	0.11
Yes	3222 (31.2%)	11215 (36.2%)		
<180 days	173	1652		
180- <360 days	1292	4436		
≥360 days	1757	5127		
History of SARS-CoV-2 molecular test ^e , n (%)	8131 (78.7%)	22539 (72.7%)	<0.01	0.14
Number of outpatient and virtual visits ^b , n (%)			<0.01	0.11
0	732 (7.1%)	1594 (5.1%)		
1-4	2672 (25.9%)	7649 (24.7%)		
5-10	2966 (28.7%)	8474 (27.3%)		
≥11	3966 (38.4%)	13291 (42.9%)		
Number of Emergency Department visits ^b , n (%)			<0.01	0.10
0	7784 (75.3%)	21943 (70.8%)		
1	1583 (15.3%)	5759 (18.6%)		

≥2	969 (9.4%)	3306 (10.7%)		
Number of hospitalizations ^b , n (%)			<0.01	0.05
0	9383 (90.8%)	28406 (91.6%)		
1	764 (7.4%)	1958 (6.3%)		
≥2	189 (1.8%)	644 (2.1%)		
Preventive care ^b , n (%)	7434 (71.9%)	22607 (72.9%)	0.05	0.02
Medicaid, n (%)	1592 (15.4%)	5894 (19.0%)	<0.01	0.10
Neighborhood median household income, n (%)			0.02	0.04
< \$40,000	180 (1.7%)	603 (1.9%)		
\$40,000-\$59,999	1728 (16.7%)	5037 (16.2%)		
\$60,000-\$79,999	2602 (25.2%)	7597 (24.5%)		
≥\$80,000	5781 (55.9%)	17684 (57.0%)		
Unknown	45 (0.4%)	87 (0.3%)		
Medical center area ^f			<0.01	0.17
Month of specimen collection, n (%)			<0.01	0.07
September - October 2022	1590 (15.4%)	5101 (16.5%)		
November - December 2022	4582 (44.3%)	12771 (41.2%)		
January - February 2023	2186 (21.1%)	7033 (22.7%)		
March - April 2023	1064 (10.3%)	3395 (10.9%)		
May - June 2023	914 (8.8%)	2708 (8.7%)		
Specimen type, n (%)			<0.01	0.15
Nasopharyngeal/oropharyngeal swab	8934 (86.4%)	28224 (91.0%)		
Saliva	1402 (13.6%)	2784 (9.0%)		
Vaccination status, n (%)			0.74	<0.01
Bivalent vaccinated	3077 (29.8%)	9285 (29.9%)		
Unvaccinated	7259 (70.2%)	21723 (70.1%)		
Antiviral therapy within 7 days after the index date n (%)			N/A	N/A
Yes	1372 (13.3%)	N/A	N/A	N/A
Nirmatrelvir/ritonavir	1352	N/A	N/A	N/A
Molnupiravir	6	N/A	N/A	N/A
Remdesivir	14	N/A	N/A	N/A

ASD = absolute standardized difference, sd = standard deviation, N/A = not applicable

^a Defined in the two years prior to specimen collection date

^b Defined in the one year prior to specimen collection date

^c Possible range: 0-29. Quan, H., et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *American Journal of Epidemiology* 173.6 (2011): 676-682.

^d Possible range: 0-1. Kim, D.H., et al. Measuring frailty in Medicare data: development and validation of a claims-based frailty index. *The Journals of Gerontology: Series A* 73.7 (2018): 980-987.

^e Defined based on all available medical records from March 1, 2020 to specimen collection date

^f Frequency and percent for the 19 medical center areas not shown

Supplementary Table 3. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥2 monovalent mRNA vaccines against infection and severe outcomes with SARS-CoV-2 variants by time since vaccination

Subvariant/Time since vaccination	Test Positive		Test Negative		Odds Ratio (95% CI)		rVE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	≥2 doses monovalent mRNA vaccinated (%)	mRNA-1273 bivalent vaccinated (%)	≥2 doses monovalent mRNA vaccinated (%)	Unadjusted	Adjusted ^{b,c}	Unadjusted	Adjusted ^{b,c}
BA.4/BA.5								
SARS-CoV-2 infection	751 (10.3%)	6540 (89.7%)	3373 (15.4%)	18500 (84.6%)	0.597 (0.547, 0.652)	0.532 (0.484, 0.585)	40.3% (34.8%, 45.3%)	46.8% (41.5%, 51.6%)
14-60 days	432 (6.2%)	6540 (93.8%)	2186 (10.6%)	18500 (89.4%)	0.559 (0.502, 0.622)	0.473 (0.422, 0.531)	44.1% (37.8%, 49.8%)	52.7% (46.9%, 57.8%)
61-120 days	293 (4.3%)	6540 (95.7%)	1096 (5.6%)	18500 (94.4%)	0.756 (0.663, 0.863)	0.606 (0.525, 0.699)	24.4% (13.7%, 33.7%)	39.4% (30.1%, 47.5%)
121-180 days	25 (0.4%)	6540 (99.6%)	91 (0.5%)	18500 (99.5%)	0.777 (0.499, 1.211)	0.645 (0.405, 1.029)	22.3% (-17.4%, 50.1%)	35.5% (-2.8%, 59.5%)
>180 days	1 (0.0%)	6540 (100.0%)	0 (0.0%)	18500 (100.0%)	N/A	N/A	N/A	N/A
ED/UC encounters	218 (10.1%)	1930 (89.9%)	1190 (18.5%)	5254 (81.5%)	0.461 (0.392, 0.542)	0.417 (0.349, 0.500)	53.9% (45.8%, 60.8%)	58.3% (50.0%, 65.1%)
14-60 days ^d	125 (6.1%)	1930 (93.9%)	743 (12.4%)	5254 (87.6%)	0.458 (0.376, 0.557)	0.407 (0.330, 0.503)	54.2% (44.3%, 62.4%)	59.3% (49.7%, 67.0%)
61-120 days ^d	82 (4.1%)	1930 (95.9%)	410 (7.2%)	5254 (92.8%)	0.544 (0.427, 0.694)	0.490 (0.376, 0.637)	45.6% (30.6%, 57.3%)	51.0% (36.3%, 62.4%)
121-180 days ^d	10 (0.5%)	1930 (99.5%)	37 (0.7%)	5254 (99.3%)	0.736 (0.365, 1.482)	0.668 (0.320, 1.393)	26.4% (-32.5%, 63.5%)	33.2% (-28.2%, 68.0%)
>180 days ^d	1 (0.1%)	1930 (99.9%)	0 (0.0%)	5254 (100.0%)	N/A	N/A	N/A	N/A
COVID-19 hospitalization ^d	24 (9.3%)	235 (90.7%)	196 (25.2%)	581 (74.8%)	0.289 (0.183, 0.456)	0.328 (0.192, 0.561)	71.1% (54.4%, 81.7%)	67.2% (43.9%, 80.8%)
14-60 days ^d	12 (4.9%)	235 (95.1%)	129 (18.2%)	581 (81.8%)	0.230 (0.125, 0.424)	0.287 (0.149, 0.551)	77.0% (57.6%, 87.5%)	71.3% (44.9%, 85.1%)
61-120 days ^d	11 (4.5%)	235 (95.5%)	65 (10.1%)	581 (89.9%)	0.418 (0.217, 0.807)	0.480 (0.227, 1.012)	58.2% (19.3%, 78.3%)	52.0% (-1.2%, 77.3%)
121-180 days ^d	0 (0.0%)	235 (100.0%)	2 (0.3%)	581 (99.7%)	N/A	N/A	N/A	N/A
>180 days ^d	1 (0.4%)	235 (99.6%)	0 (0.0%)	581 (100.0%)	N/A	N/A	N/A	N/A
COVID-19 hospital death ^{d,e}	2 (11.8%)	15 (88.2%)	13 (25.5%)	38 (74.5%)	0.358 (0.069, 1.869)	0.469 (0.035, 6.337)	64.2% (-46.5%, 93.1%)	53.1% (-84.2%, 96.5%)
XBB								
SARS-CoV-2 infection	799 (21.1%)	2981 (78.9%)	2240 (19.8%)	9100 (80.2%)	1.095 (0.997, 1.203)	0.907 (0.818, 1.006)	-8.7% (-16.9%, 0.3%)	9.3% (-0.6%, 18.2%)
14-60 days	76 (2.5%)	2981 (97.5%)	356 (3.8%)	9100 (96.2%)	0.652 (0.507, 0.838)	0.512 (0.393, 0.666)	34.8% (16.2%, 49.3%)	48.8% (33.4%, 60.7%)
61-120 days	212 (6.6%)	2981 (93.4%)	698 (7.1%)	9100 (92.9%)	0.927 (0.791, 1.087)	0.740 (0.623, 0.879)	7.3% (-8.0%, 20.9%)	26.0% (12.1%, 37.7%)
121-180 days	265 (8.2%)	2981 (91.8%)	662 (6.8%)	9100 (93.2%)	1.222 (1.054, 1.417)	1.041 (0.887, 1.221)	-18.2% (-29.5%, -5.1%)	-3.9% (-18.1%, 11.3%)
>180 days	246 (7.6%)	2981 (92.4%)	524 (5.4%)	9100 (94.6%)	1.433 (1.225, 1.677)	1.225 (1.030, 1.456)	-30.2% (-40.4%, -18.4%)	-18.3% (-31.3%, -2.9%)

ED/UC encounters	343 (20.8%)	1307 (79.2%)	1113 (22.5%)	3837 (77.5%)	0.899 (0.782, 1.035)	0.741 (0.633, 0.868)	10.1% (-3.4%, 21.8%)	25.9% (13.2%, 36.7%)
14-60 days ^d	20 (1.5%)	1307 (98.5%)	158 (4.0%)	3837 (96.0%)	0.372 (0.232, 0.594)	0.293 (0.180, 0.476)	62.8% (40.6%, 76.8%)	70.7% (52.4%, 82.0%)
61-120 days ^d	92 (6.6%)	1307 (93.4%)	304 (7.3%)	3837 (92.7%)	0.888 (0.698, 1.131)	0.697 (0.537, 0.905)	11.2% (-11.6%, 30.2%)	30.3% (9.5%, 46.3%)
121-180 days ^d	118 (8.3%)	1307 (91.7%)	357 (8.5%)	3837 (91.5%)	0.970 (0.781, 1.206)	0.843 (0.668, 1.063)	3.0% (-17.1%, 21.9%)	15.7% (-6.0%, 33.2%)
>180 days ^d	113 (8.0%)	1307 (92.0%)	294 (7.1%)	3837 (92.9%)	1.128 (0.900, 1.414)	0.980 (0.764, 1.257)	-11.4% (-29.3%, 10.0%)	2.0% (-20.4%, 23.6%)
COVID-19 hospitalization ^d	40 (18.9%)	172 (81.1%)	209 (32.9%)	427 (67.1%)	0.482 (0.329, 0.705)	0.401 (0.255, 0.630)	51.8% (29.5%, 67.1%)	59.9% (37.0%, 74.5%)
14-60 days ^d	2 (1.1%)	172 (98.9%)	27 (5.9%)	427 (94.1%)	0.184 (0.043, 0.782)	0.121 (0.026, 0.562)	81.6% (21.8%, 95.7%)	87.9% (43.8%, 97.4%)
61-120 days ^d	7 (3.9%)	172 (96.1%)	54 (11.2%)	427 (88.8%)	0.322 (0.144, 0.721)	0.219 (0.090, 0.529)	67.8% (27.9%, 85.6%)	78.1% (47.1%, 91.0%)
121-180 days ^d	14 (7.5%)	172 (92.5%)	72 (14.4%)	427 (85.6%)	0.483 (0.265, 0.879)	0.429 (0.222, 0.830)	51.7% (12.1%, 73.5%)	57.1% (17.0%, 77.8%)
>180 days ^d	17 (9.0%)	172 (91.0%)	56 (11.6%)	427 (88.4%)	0.754 (0.426, 1.334)	0.700 (0.363, 1.351)	24.6% (-25.0%, 57.4%)	30.0% (-26.0%, 63.7%)
COVID-19 hospital death ^{d,e,f}	4 (28.6%)	10 (71.4%)	17 (40.5%)	25 (59.5%)	0.602 (0.166, 2.174)	0.682 (0.076, 6.133)	39.8% (-54.0%, 83.4%)	31.8% (-83.7%, 92.4%)

BMI= body mass index, ED/UC = emergency department/urgent care, OR = odds ratio, rVE = relative vaccine effectiveness, N/A = not applicable

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1 .

^b Applied conditional logistic models conditioned on matched pairs for SARS-CoV-2 infection, ED/UC encounters, hospitalization and hospital death outcomes. Models for time since vaccination analyses are unconditional logistic models, adjusted for age, sex, race/ethnicity, and month of specimen collection, in addition to the covariates listed below.

^c Adjusted for days since last monovalent dose, time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, number of emergency department visits, BMI, Charlson comorbidity score, frailty index, pregnancy, medical center area, and number of monovalent doses prior to index date.

^d Medical center area dropped due to lack of model convergence.

^e BMI, Charlson comorbidity score, frailty index, and pregnancy dropped due to lack of model convergence.

^f Number of monovalent doses prior to index date dropped due to lack of model convergence.

Supplementary Table 4. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against infection and severe outcomes with SARS-CoV-2 variants by time since vaccination

Subvariant/Time since vaccination	Test Positive		Test Negative		Odds Ratio (95% CI)		VE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	Unadjusted	Adjusted ^{b,c}	Unadjusted	Adjusted ^{b,c}
BA.4/BA.5								
SARS-CoV-2 infection ^d	751 (22.1%)	2646 (77.9%)	2478 (24.3%)	7713 (75.7%)	0.825 (0.735, 0.925)	0.814 (0.721, 0.919)	17.5% (7.5%, 26.5%)	18.6% (8.1%, 27.9%)
14-60 days ^d	432 (14.0%)	2646 (86.0%)	1615 (17.3%)	7713 (82.7%)	0.780 (0.695, 0.875)	0.707 (0.618, 0.809)	22.0% (12.5%, 30.5%)	29.3% (19.1%, 38.2%)
61-120 days ^d	293 (10.0%)	2646 (90.0%)	791 (9.3%)	7713 (90.7%)	1.080 (0.938, 1.243)	0.972 (0.826, 1.143)	-7.4% (-19.6%, 6.2%)	2.8% (-12.5%, 17.4%)
121-180 days ^d	25 (0.9%)	2646 (99.1%)	70 (0.9%)	7713 (99.1%)	1.041 (0.658, 1.647)	1.097 (0.670, 1.796)	-3.9% (-39.3%, 34.2%)	-8.8% (-44.3%, 33.0%)
>180 days ^d	1 (0.0%)	2646 (100.0%)	2 (0.0%)	7713 (100.0%)	1.458 (0.132, 16.08)	1.241 (0.078, 19.75)	-31.4% (-93.8%, 86.8%)	-19.4% (-94.9%, 92.2%)
ED/UC encounters ^d	218 (19.4%)	905 (80.6%)	920 (27.3%)	2449 (72.7%)	0.507 (0.413, 0.622)	0.481 (0.387, 0.597)	49.3% (37.8%, 58.7%)	51.9% (40.3%, 61.3%)
14-60 days ^d	125 (12.1%)	905 (87.9%)	592 (19.5%)	2449 (80.5%)	0.571 (0.464, 0.703)	0.444 (0.349, 0.566)	42.9% (29.7%, 53.6%)	55.6% (43.4%, 65.1%)
61-120 days ^d	82 (8.3%)	905 (91.7%)	302 (11.0%)	2449 (89.0%)	0.735 (0.569, 0.949)	0.581 (0.435, 0.778)	26.5% (5.1%, 43.1%)	41.9% (22.2%, 56.5%)
121-180 days ^d	10 (1.1%)	905 (98.9%)	24 (1.0%)	2449 (99.0%)	1.128 (0.537, 2.367)	1.055 (0.473, 2.353)	-11.3% (-57.8%, 46.3%)	-5.2% (-57.5%, 52.7%)
>180 days ^d	1 (0.1%)	905 (99.9%)	2 (0.1%)	2449 (99.9%)	1.353 (0.123, 14.94)	1.448 (0.082, 25.70)	-26.1% (-93.3%, 87.7%)	-30.9% (-96.1%, 91.8%)
COVID-19 hospitalization ^{d,e}	24 (19.8%)	97 (80.2%)	173 (47.7%)	190 (52.3%)	0.211 (0.121, 0.368)	0.216 (0.112, 0.417)	78.9% (63.2%, 87.9%)	78.4% (58.3%, 88.8%)
14-60 days ^{d,e}	12 (11.0%)	97 (89.0%)	101 (34.7%)	190 (65.3%)	0.233 (0.122, 0.444)	0.231 (0.113, 0.473)	76.7% (55.6%, 87.8%)	76.9% (52.7%, 88.7%)
61-120 days ^{d,e}	11 (10.2%)	97 (89.8%)	67 (26.1%)	190 (73.9%)	0.322 (0.162, 0.637)	0.321 (0.152, 0.679)	67.8% (36.3%, 83.8%)	67.9% (32.1%, 84.8%)
121-180 days ^{d,e}	0 (0.0%)	97 (100.0%)	5 (2.6%)	190 (97.4%)	N/A	N/A	N/A	N/A
>180 days ^{d,e}	1 (1.0%)	97 (99.0%)	0 (0.0%)	190 (100.0%)	N/A	N/A	N/A	N/A
COVID-19 hospital death ^{d,e,f}	2 (22.2%)	7 (77.8%)	10 (37.0%)	17 (63.0%)	0.518 (0.097, 2.755)	0.541 (0.099, 2.947)	48.2% (-63.7%, 90.3%)	45.9% (-66.1%, 90.1%)
XBB								
SARS-CoV-2 infection ^d	799 (47.1%)	898 (52.9%)	2123 (41.7%)	2968 (58.3%)	1.377 (1.203, 1.576)	1.334 (1.156, 1.538)	-27.4% (-36.5%, -16.9%)	-25.0% (-35.0%, -13.5%)
14-60 days ^d	76 (7.8%)	898 (92.2%)	308 (9.4%)	2968 (90.6%)	0.816 (0.628, 1.060)	0.788 (0.593, 1.048)	18.4% (-5.6%, 37.2%)	21.2% (-4.6%, 40.7%)
61-120 days ^d	212 (19.1%)	898 (80.9%)	620 (17.3%)	2968 (82.7%)	1.130 (0.951, 1.343)	1.154 (0.948, 1.406)	-11.5% (-25.6%, 4.9%)	-13.4% (-28.9%, 5.2%)

121-180 days ^d	265 (22.8%)	898 (77.2%)	683 (18.7%)	2968 (81.3%)	1.282 (1.092, 1.505)	1.429 (1.184, 1.724)	-22.0% (-33.6%, -8.5%)	-30.0% (-42.0%, -15.5%)
>180 days ^d	246 (21.5%)	898 (78.5%)	512 (14.7%)	2968 (85.3%)	1.588 (1.341, 1.881)	1.948 (1.578, 2.405)	-37.0% (-46.8%, -25.4%)	-48.7% (-58.4%, -36.6%)
ED/UC encounters	343 (42.1%)	472 (57.9%)	1032 (42.2%)	1413 (57.8%)	0.992 (0.815, 1.209)	0.918 (0.739, 1.139)	0.8% (-17.3%, 18.5%)	8.2% (-12.2%, 26.1%)
14-60 days	20 (4.1%)	472 (95.9%)	139 (9.0%)	1413 (91.0%)	Tab	0.396 (0.237, 0.662)	56.9% (30.4%, 73.3%)	60.4% (33.8%, 76.3%)
61-120 days	92 (16.3%)	472 (83.7%)	278 (16.4%)	1413 (83.6%)	0.991 (0.766, 1.282)	0.903 (0.674, 1.210)	0.9% (-22.0%, 23.4%)	9.7% (-17.3%, 32.6%)
121-180 days	118 (20.0%)	472 (80.0%)	341 (19.4%)	1413 (80.6%)	1.036 (0.820, 1.309)	0.978 (0.740, 1.292)	-3.5% (-23.6%, 18.0%)	2.2% (-22.6%, 26.0%)
>180 days	113 (19.3%)	472 (80.7%)	274 (16.2%)	1413 (83.8%)	1.235 (0.969, 1.574)	1.172 (0.874, 1.570)	-19.0% (-36.5%, 3.1%)	-14.6% (-36.3%, 12.6%)
COVID-19 hospitalization ^{d,e}	40 (43.0%)	53 (57.0%)	194 (69.5%)	85 (30.5%)	0.287 (0.170, 0.486)	0.267 (0.146, 0.488)	71.3% (51.4%, 83.0%)	73.3% (51.2%, 85.4%)
14-60 days ^{d,e}	2 (3.6%)	53 (96.4%)	35 (29.2%)	85 (70.8%)	0.092 (0.021, 0.397)	0.066 (0.014, 0.314)	90.8% (60.3%, 97.9%)	93.4% (68.6%, 98.6%)
61-120 days ^{d,e}	7 (11.7%)	53 (88.3%)	58 (40.6%)	85 (59.4%)	0.194 (0.082, 0.456)	0.146 (0.056, 0.380)	80.6% (54.4%, 91.8%)	85.4% (62.0%, 94.4%)
121-180 days ^{d,e}	14 (20.9%)	53 (79.1%)	55 (39.3%)	85 (60.7%)	0.408 (0.207, 0.806)	0.362 (0.164, 0.799)	59.2% (19.4%, 79.3%)	63.8% (20.1%, 83.6%)
>180 days ^{d,e}	17 (24.3%)	53 (75.7%)	46 (35.1%)	85 (64.9%)	0.593 (0.308, 1.139)	0.576 (0.268, 1.237)	40.7% (-12.2%, 69.2%)	42.4% (-19.2%, 73.2%)
COVID-19 hospital death ^{d,e,f}	4 (80.0%)	1 (20.0%)	13 (86.7%)	2 (13.3%)	0.577 (0.033, 10.25)	0.690 (0.035, 13.55)	42.3% (-90.2%, 96.7%)	31.0% (-92.6%, 96.5%)

BMI= body mass index, ED/UC = emergency department/urgent care, OR = odds ratio, VE = vaccine effectiveness, N/A = not applicable

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1 .

^b Applied conditional logistic models conditioned on matched pairs for SARS-CoV-2 infection, ED/UC encounters, hospitalization and hospital death outcomes. Models for time since vaccination analyses are unconditional logistic models, adjusted for age, sex, race/ethnicity, and month of specimen collection, in addition to the covariates listed below.

^c Adjusted for time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, BMI, pregnancy, specimen type, and medical center area.

^d Medical center area dropped due to lack of model convergence.

^e Specimen type and pregnancy dropped due to lack of model convergence.

^f BMI and time since history of SARS-CoV-2 infection dropped due to lack of model convergence.

Supplementary Table 5. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥2 monovalent mRNA vaccines against infection and severe outcomes with SARS-CoV-2 variants by age group

Subvariant/Age group/Outcome	Test Positive		Test Negative		Odds Ratio (95% CI)		rVE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	≥2 doses monovalent mRNA vaccinated (%)	mRNA-1273 bivalent vaccinated (%)	≥2 doses monovalent mRNA vaccinated (%)	Unadjusted	Adjusted ^{b,c}	Unadjusted	Adjusted ^{b,c}
BA.4/BA.5								
Aged ≤17 years								
SARS-CoV-2 infection ^{d,e}	4 (9.5%)	38 (90.5%)	10 (7.9%)	116 (92.1%)	1.591 (0.254, 9.950)	1.518 (0.240, 9.605)	-37.1% (-90.0%, 74.6%)	-34.1% (-89.6%, 76.0%)
ED/UC encounters	2 (14.3%)	12 (85.7%)	7 (16.7%)	35 (83.3%)	N/A	N/A	N/A	N/A
COVID-19 hospitalization	0	0	0	0	N/A	N/A	N/A	N/A
COVID-19 hospital death	0	0	0	0	N/A	N/A	N/A	N/A
Aged 18-64 years								
SARS-CoV-2 infection	446 (8.4%)	4878 (91.6%)	1928 (12.1%)	14044 (87.9%)	0.647 (0.579, 0.724)	0.568 (0.504, 0.640)	35.3% (27.6%, 42.1%)	43.2% (36.0%, 49.6%)
ED/UC encounters ^d	100 (8.4%)	1086 (91.6%)	441 (12.4%)	3117 (87.6%)	0.631 (0.499, 0.799)	0.552 (0.428, 0.713)	36.9% (20.1%, 50.1%)	44.8% (28.7%, 57.2%)
COVID-19 hospitalization ^{d,f}	1 (2.9%)	33 (97.1%)	11 (10.8%)	91 (89.2%)	0.273 (0.035, 2.112)	0.267 (0.007, 9.674)	72.7% (-52.7%, 96.5%)	73.3% (-89.7%, 99.3%)
COVID-19 hospital death	0 (0.0%)	3 (100.0%)	0 (0.0%)	9 (100.0%)	N/A	N/A	N/A	N/A
Aged ≥65 years								
SARS-CoV-2 infection	301 (15.6%)	1624 (84.4%)	1435 (24.8%)	4340 (75.2%)	0.522 (0.452, 0.603)	0.489 (0.417, 0.573)	47.8% (39.7%, 54.8%)	51.1% (42.7%, 58.3%)
ED/UC encounters ^d	116 (12.2%)	832 (87.8%)	742 (26.1%)	2102 (73.9%)	0.362 (0.290, 0.451)	0.380 (0.298, 0.485)	63.8% (54.9%, 71.0%)	62.0% (51.5%, 70.2%)
COVID-19 hospitalization ^d	23 (10.2%)	202 (89.8%)	185 (27.4%)	490 (72.6%)	0.290 (0.181, 0.463)	0.319 (0.182, 0.559)	71.0% (53.7%, 81.9%)	68.1% (44.1%, 81.8%)
COVID-19 hospital death ^{d,g}	2 (14.3%)	12 (85.7%)	13 (31.0%)	29 (69.0%)	0.358 (0.069, 1.869)	0.257 (0.022, 3.062)	64.2% (-46.5%, 93.1%)	74.3% (-67.3%, 97.8%)
XBB								
Aged ≤17 years								
SARS-CoV-2 infection	4 (3.2%)	121 (96.8%)	5 (1.3%)	370 (98.7%)	2.637 (0.646, 10.76)	3.691 (0.809, 16.84)	-62.1% (-90.7%, 35.4%)	-72.9% (-94.1%, 19.1%)
ED/UC encounters	0 (0.0%)	53 (100.0%)	4 (2.5%)	155 (97.5%)	N/A	N/A	N/A	N/A
COVID-19 hospitalization	0	0	0	0	N/A	N/A	N/A	N/A
COVID-19 hospital death	0	0	0	0	N/A	N/A	N/A	N/A
Aged 18-64 years								
SARS-CoV-2 infection	454 (17.1%)	2199 (82.9%)	1224 (15.4%)	6735 (84.6%)	1.140 (1.012, 1.285)	0.968 (0.851, 1.102)	-12.3% (-22.2%, -1.1%)	4.5% (-8.1%, 16.2%)

ED/UC encounters	150 (16.0%)	786 (84.0%)	445 (15.8%)	2363 (84.2%)	1.014 (0.826, 1.245)	0.845 (0.671, 1.063)	-1.4% (-19.7%, 17.4%)	16.8% (-4.6%, 34.0%)
COVID-19 hospitalization ^{d,f}	4 (9.5%)	38 (90.5%)	36 (28.6%)	90 (71.4%)	0.268 (0.090, 0.800)	0.091 (0.018, 0.467)	73.2% (20.0%, 91.0%)	90.9% (53.3%, 98.2%)
COVID-19 hospital death	1 (50.0%)	1 (50.0%)	2 (33.3%)	4 (66.7%)	1.732 (0.098, 30.76)	N/A	-42.3% (-96.7%, 90.2%)	N/A
Aged ≥65 years								
SARS-CoV-2 infection ^d	341 (34.0%)	661 (66.0%)	1011 (33.6%)	1995 (66.4%)	1.018 (0.875, 1.184)	0.801 (0.673, 0.953)	-1.8% (-15.6%, 12.5%)	19.9% (4.7%, 32.7%)
ED/UC encounters ^d	193 (29.2%)	468 (70.8%)	664 (33.5%)	1319 (66.5%)	0.820 (0.677, 0.993)	0.698 (0.561, 0.868)	18.0% (0.7%, 32.3%)	30.2% (13.2%, 43.9%)
COVID-19 hospitalization ^d	36 (21.2%)	134 (78.8%)	173 (33.9%)	337 (66.1%)	0.532 (0.353, 0.801)	0.462 (0.285, 0.748)	46.8% (19.9%, 64.7%)	53.8% (25.2%, 71.5%)
COVID-19 hospital death ^{d,g}	3 (25.0%)	9 (75.0%)	15 (41.7%)	21 (58.3%)	0.472 (0.111, 2.014)	0.248 (0.018, 3.430)	52.8% (-50.3%, 88.9%)	75.2% (-70.8%, 98.2%)

BMI= body mass index, ED/UC = emergency department/urgent care, OR = odds ratio, rVE = relative vaccine effectiveness, N/A = not applicable

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1 .

^b Conditional logistic models conditioned on matched pairs with additional adjustments.

^c Model Adjustment

Age ≤ 17 years old group adjusted for days since last monovalent dose, number of outpatient and virtual visits, time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, and medical center area.

Age 18-64 years old and age ≥ 65 years groups adjusted for days since last monovalent dose, number of emergency department visits, number of outpatient and virtual visits, time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, BMI, Charlson comorbidity score, frailty index, medical center area, and number of monovalent doses prior to index date. Pregnancy added only to age 18-64 years old group.

^d Medical center area dropped due to lack of model convergence.

^e Time since history of SARS-CoV-2 infection dropped due to lack of model convergence.

^f BMI dropped due to lack of model convergence.

^g History of SARS-CoV-2 molecular test and Charlson comorbidity score dropped due to lack of model convergence.

Supplementary Table 6. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against infection and severe outcomes with SARS-CoV-2 variants by age group

Subvariant/Age group/Outcome	Test Positive		Test Negative		Odds Ratio (95% CI)		VE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	Unadjusted	Adjusted ^{b,c}	Unadjusted	Adjusted ^{b,c}
BA.4/BA.5								
Aged ≤17 years								
SARS-CoV-2 infection	4 (0.5%)	828 (99.5%)	14 (0.6%)	2482 (99.4%)	0.857 (0.282, 2.604)	0.826 (0.257, 2.656)	14.3% (-61.6%, 71.8%)	17.4% (-62.3%, 74.3%)
ED/UC encounters ^d	2 (0.6%)	326 (99.4%)	2 (0.2%)	982 (99.8%)	3.000 (0.423, 21.30)	5.974 (0.745, 47.90)	-66.7% (-95.3%, 57.7%)	-83.3% (-97.9%, 25.5%)
COVID-19 hospitalization	0 (0.0%)	6 (100.0%)	1 (5.6%)	17 (94.4%)	N/A	N/A	N/A	N/A
COVID-19 hospital death	0	0	0	0	N/A	N/A	N/A	N/A
Aged 18-64 years								
SARS-CoV-2 infection ^d	446 (22.7%)	1518 (77.3%)	1348 (22.9%)	4544 (77.1%)	0.988 (0.860, 1.134)	0.993 (0.857, 1.150)	1.2% (-11.8%, 14.0%)	0.7% (-13.0%, 14.3%)
ED/UC encounters ^d	100 (21.1%)	375 (78.9%)	353 (24.8%)	1072 (75.2%)	0.766 (0.578, 1.016)	0.707 (0.523, 0.955)	23.4% (-1.6%, 42.2%)	29.3% (4.5%, 47.7%)
COVID-19 hospitalization ^{d,e,f}	1 (5.6%)	17 (94.4%)	16 (29.6%)	38 (70.4%)	0.114 (0.013, 0.978)	0.089 (0.009, 0.893)	88.6% (2.2%, 98.7%)	91.1% (10.7%, 99.1%)
COVID-19 hospital death	0	0	0	0	N/A	N/A	N/A	N/A
Aged ≥65 years								
SARS-CoV-2 infection	301 (50.1%)	300 (49.9%)	1116 (61.9%)	687 (38.1%)	0.557 (0.453, 0.684)	0.581 (0.460, 0.733)	44.3% (31.6%, 54.7%)	41.9% (26.7%, 54.0%)
ED/UC encounters	116 (36.3%)	204 (63.8%)	565 (58.9%)	395 (41.1%)	0.329 (0.245, 0.441)	0.298 (0.208, 0.426)	67.1% (55.9%, 75.5%)	70.2% (57.4%, 79.2%)
COVID-19 hospitalization ^d	23 (23.7%)	74 (76.3%)	156 (53.6%)	135 (46.4%)	0.224 (0.126, 0.400)	0.260 (0.132, 0.509)	77.6% (60.0%, 87.4%)	74.0% (49.1%, 86.8%)
COVID-19 hospital death ^{d,e,g}	2 (22.2%)	7 (77.8%)	10 (37.0%)	17 (63.0%)	0.518 (0.097, 2.755)	0.263 (0.038, 1.825)	48.2% (-63.7%, 90.3%)	73.7% (-45.2%, 96.2%)
XBB								
Aged ≤17 years								
SARS-CoV-2 infection	4 (1.2%)	319 (98.8%)	14 (1.4%)	955 (98.6%)	0.852 (0.275, 2.640)	0.980 (0.296, 3.250)	14.8% (-62.1%, 72.5%)	2.0% (-69.2%, 70.4%)
ED/UC encounters	0 (0.0%)	183 (100.0%)	10 (1.8%)	539 (98.2%)	N/A	N/A	N/A	N/A
COVID-19 hospitalization	0 (0.0%)	2 (100.0%)	0 (0.0%)	6 (100.0%)	N/A	N/A	N/A	N/A
COVID-19 hospital death	0	0	0	0	N/A	N/A	N/A	N/A
Aged 18-64 years								
SARS-CoV-2 infection ^d	454 (49.6%)	461 (50.4%)	1084 (39.5%)	1661 (60.5%)	1.599 (1.360, 1.880)	1.648 (1.384, 1.962)	-37.5% (-46.8%, -26.5%)	-39.3% (-49.0%, -27.8%)

ED/UC encounters ^d	150 (43.1%)	198 (56.9%)	399 (38.2%)	645 (61.8%)	1.268 (0.971, 1.657)	1.357 (1.019, 1.806)	-21.2% (-39.6%, 2.9%)	-26.3% (-44.6%, -1.9%)
COVID-19 hospitalization ^{d,e,f}	4 (26.7%)	11 (73.3%)	18 (40.0%)	27 (60.0%)	0.347 (0.060, 1.990)	0.353 (0.043, 2.928)	65.3% (-49.7%, 94.0%)	64.7% (-65.8%, 95.7%)
COVID-19 hospital death	1 (100.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	N/A	N/A	N/A	N/A
Aged ≥65 years								
SARS-CoV-2 infection ^d	341 (74.3%)	118 (25.7%)	1025 (74.4%)	352 (25.6%)	0.992 (0.779, 1.265)	0.901 (0.695, 1.169)	0.8% (-20.9%, 22.1%)	9.9% (-14.5%, 30.5%)
ED/UC encounters ^d	193 (68.0%)	91 (32.0%)	623 (73.1%)	229 (26.9%)	0.781 (0.584, 1.044)	0.725 (0.530, 0.992)	21.9% (-4.3%, 41.6%)	27.5% (0.8%, 47.0%)
COVID-19 hospitalization ^{d,e}	36 (47.4%)	40 (52.6%)	176 (77.2%)	52 (22.8%)	0.282 (0.163, 0.489)	0.267 (0.148, 0.482)	71.8% (51.1%, 83.7%)	73.3% (51.8%, 85.2%)
COVID-19 hospital death	3 (75.0%)	1 (25.0%)	10 (83.3%)	2 (16.7%)	0.577 (0.033, 10.25)	N/A	42.3% (-90.2%, 96.7%)	N/A

BMI= body mass index, ED/UC = emergency department/urgent care, OR = odds ratio, VE = vaccine effectiveness, N/A = not applicable

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1 .

^b Conditional logistic models conditioned on matched pairs with adjustments.

^c Model Adjustment

Age ≤ 17 years old group adjusted for time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, specimen type and medical center area.

Age 18-64 years old and age ≥ 65 years groups adjusted for time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, BMI, specimen type and medical center area. Pregnancy added only to age 18-64 years old group.

^d Medical center area dropped due to lack of model convergence.

^e BMI and specimen type dropped due to lack of model convergence.

^f Pregnancy dropped due to lack of model convergence.

^g History of SARS-CoV-2 molecular test dropped due to lack of model convergence.

Supplementary Table 7. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥2 monovalent mRNA vaccines against infection and severe outcomes with SARS-CoV-2 variants among immunocompromised patients

Subvariant/Outcome	Test Positive		Test Negative		Odds Ratio (95% CI)		rVE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	≥2 doses monovalent mRNA vaccinated (%)	mRNA-1273 bivalent vaccinated (%)	≥2 doses monovalent mRNA vaccinated (%)	Unadjusted	Adjusted ^b	Unadjusted	Adjusted ^b
BA.4/BA.5								
SARS-CoV-2 infection	42 (14.1%)	255 (85.9%)	227 (16.5%)	1151 (83.5%)	0.835 (0.585, 1.192)	0.669 (0.439, 1.019)	16.5% (-16.1%, 41.5%)	33.1% (-1.9%, 56.1%)
ED/UC encounters ^{c,d}	23 (14.6%)	135 (85.4%)	246 (16.2%)	1271 (83.8%)	0.880 (0.554, 1.398)	0.879 (0.516, 1.496)	12.0% (-28.5%, 44.6%)	12.1% (-33.1%, 48.4%)
COVID-19 hospitalization ^{c,d}	4 (9.8%)	37 (90.2%)	265 (16.2%)	1369 (83.8%)	0.558 (0.197, 1.580)	0.375 (0.120, 1.169)	44.2% (-36.7%, 80.3%)	62.5% (-14.5%, 88.0%)
COVID-19 hospital death ^{c,d,e}	1 (33.3%)	2 (66.7%)	268 (16.0%)	1404 (84.0%)	2.619 (0.237, 28.99)	2.409 (0.197, 29.51)	-61.8% (-96.6%, 76.3%)	-58.5% (-96.6%, 80.3%)
XBB								
SARS-CoV-2 infection ^c	48 (27.3%)	128 (72.7%)	162 (20.5%)	628 (79.5%)	1.454 (1.000, 2.113)	1.017 (0.658, 1.570)	-31.2% (-52.7%, 0.0%)	-1.6% (-36.3%, 34.2%)
ED/UC encounters ^c	27 (25.5%)	79 (74.5%)	183 (21.3%)	677 (78.7%)	1.264 (0.793, 2.016)	0.963 (0.559, 1.660)	-20.9% (-50.4%, 20.7%)	3.7% (-39.7%, 44.1%)
COVID-19 hospitalization ^{c,d}	4 (12.9%)	27 (87.1%)	206 (22.0%)	729 (78.0%)	0.524 (0.181, 1.515)	0.327 (0.102, 1.043)	47.6% (-34.0%, 81.9%)	67.3% (-4.2%, 89.8%)
COVID-19 hospital death ^{c,d,e}	1 (33.3%)	2 (66.7%)	209 (21.7%)	754 (78.3%)	1.804 (0.163, 19.99)	1.246 (0.101, 15.44)	-44.6% (-95.0%, 83.7%)	-19.7% (-93.5%, 89.9%)

BMI= body mass index, ED/UC = emergency department/urgent care, OR = odds ratio, rVE = relative vaccine effectiveness

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1 .

^b Unconditional logistic regression models adjusted for age, sex, race/ethnicity, month of specimen collection, days since last monovalent dose, time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, number of emergency department visits, BMI, Charlson comorbidity score, frailty index, pregnancy, medical center area, and number of monovalent doses prior to index date.

^c Medical center area dropped due to lack of model convergence.

^d BMI and pregnancy dropped due to lack of model convergence.

^e Month of specimen collection, Charlson comorbidity score, frailty index, time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, number of emergency department visits, and number of monovalent doses prior to index date dropped due to lack of model convergence.

Supplementary Table 8. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against infection and severe outcomes with SARS-CoV-2 variants among immunocompromised patients

Subvariant/Outcome	Test Positive		Test Negative		Odds Ratio (95% CI)		VE (95% CI) ^b	
	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	Unadjusted	Adjusted ^a	Unadjusted	Adjusted ^c
BA.4/BA.5								
SARS-CoV-2 infection	42 (36.5%)	73 (63.5%)	179 (39.9%)	270 (60.1%)	0.868 (0.568, 1.326)	0.530 (0.297, 0.949)	13.2% (-24.6%, 43.2%)	47.0% (5.1%, 70.3%)
ED/UC encounters	23 (36.5%)	40 (63.5%)	198 (39.5%)	303 (60.5%)	0.880 (0.511, 1.515)	0.614 (0.314, 1.202)	12.0% (-34.0%, 48.9%)	38.6% (-16.8%, 68.6%)
COVID-19 hospitalization ^{c,d,e}	4 (26.7%)	11 (73.3%)	217 (39.5%)	332 (60.5%)	0.556 (0.175, 1.770)	0.225 (0.063, 0.798)	44.4% (-43.5%, 82.5%)	77.5% (20.2%, 93.7%)
COVID-19 hospital death	1 (100.0%)	0 (0.0%)	220 (39.1%)	343 (60.9%)	N/A	N/A	N/A	N/A
XBB								
SARS-CoV-2 infection ^c	48 (60.8%)	31 (39.2%)	171 (53.3%)	150 (46.7%)	1.358 (0.822, 2.244)	1.178 (0.618, 2.246)	-26.4% (-55.4%, 17.8%)	-15.1% (-55.5%, 38.2%)
ED/UC encounters ^c	27 (58.7%)	19 (41.3%)	192 (54.2%)	162 (45.8%)	1.199 (0.643, 2.236)	0.993 (0.459, 2.145)	-16.6% (-55.3%, 35.7%)	0.7% (-53.4%, 54.1%)
COVID-19 hospitalization ^{c,d}	4 (33.3%)	8 (66.7%)	215 (55.4%)	173 (44.6%)	0.402 (0.119, 1.358)	0.306 (0.080, 1.177)	59.8% (-26.4%, 88.1%)	69.4% (-15.1%, 92.0%)
COVID-19 hospital death	1 (100.0%)	0 (0.0%)	218 (54.6%)	181 (45.4%)	N/A	N/A	N/A	N/A

BMI= body mass index, ED/UC = emergency department/urgent care, OR = odds ratio, VE = vaccine effectiveness, N/A = not applicable

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1 .

^b Unconditional logistic regression models adjusted for age, sex, race/ethnicity, month of specimen collection, time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, BMI, pregnancy, and specimen type.

^c Pregnancy dropped due to lack of model convergence.

^d BMI and specimen type dropped due to lack of model convergence.

^e Month of specimen collection and history of SARS-CoV-2 molecular test dropped due to lack of model convergence.

Supplementary Table 9. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥ 2 monovalent mRNA vaccines against infection and severe outcomes with SARS-CoV-2 variants among those with history of SARS-CoV-2 infection

Subvariant/Outcome	Test Positive		Test Negative		Odds Ratio (95% CI)		rVE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	≥ 2 doses monovalent mRNA vaccinated (%)	mRNA-1273 bivalent vaccinated (%)	≥ 2 doses monovalent mRNA vaccinated (%)	Unadjusted	Adjusted ^b	Unadjusted	Adjusted ^b
BA.4/BA.5								
SARS-CoV-2 infection	91 (5.9%)	1453 (94.1%)	1014 (12.7%)	6942 (87.3%)	0.429 (0.343, 0.535)	0.423 (0.333, 0.537)	57.1% (46.5%, 65.7%)	57.7% (46.3%, 66.7%)
ED/UC encounters ^c	23 (6.9%)	308 (93.1%)	1082 (11.8%)	8087 (88.2%)	0.558 (0.364, 0.857)	0.456 (0.289, 0.720)	44.2% (14.3%, 63.6%)	54.4% (28.0%, 71.1%)
COVID-19 hospitalization ^{c,d}	1 (3.8%)	25 (96.2%)	1104 (11.7%)	8370 (88.3%)	0.303 (0.041, 2.240)	0.154 (0.020, 1.207)	69.7% (-55.4%, 95.9%)	84.6% (-17.1%, 98.0%)
COVID-19 hospital death	0 (0.0%)	2 (100.0%)	1105 (11.6%)	8393 (88.4%)	N/A	N/A	N/A	N/A
XBB								
SARS-CoV-2 infection	196 (15.5%)	1071 (84.5%)	653 (15.6%)	3536 (84.4%)	0.991 (0.833, 1.179)	0.964 (0.795, 1.169)	0.9% (-15.2%, 16.7%)	3.6% (-14.4%, 20.5%)
ED/UC encounters ^c	72 (16.1%)	376 (83.9%)	777 (15.5%)	4231 (84.5%)	1.043 (0.801, 1.357)	0.845 (0.632, 1.128)	-4.1% (-26.3%, 19.9%)	15.5% (-11.4%, 36.8%)
COVID-19 hospitalization ^{c,d,e}	5 (12.8%)	34 (87.2%)	844 (15.6%)	4573 (84.4%)	0.797 (0.311, 2.043)	0.382 (0.140, 1.042)	20.3% (-51.1%, 68.9%)	61.8% (-4.0%, 86.0%)
COVID-19 hospital death	0 (0.0%)	1 (100.0%)	849 (15.6%)	4606 (84.4%)	N/A	N/A	N/A	N/A

BMI= body mass index, ED/UC = emergency department/urgent care, OR = odds ratio, rVE = relative vaccine effectiveness, N/A = not applicable

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1 .

^b Unconditional logistic regression models adjusted for age, sex, race/ethnicity, month of specimen collection, days since last monovalent dose, time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, number of emergency department visits, BMI, Charlson comorbidity score, frailty index, pregnancy, medical center area, and number of monovalent doses prior to index date.

^c Medical center area dropped due to lack of model convergence.

^d BMI and pregnancy dropped due to lack of model convergence.

^e Frailty index dropped due to lack of model convergence.

Supplementary Table 10. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against infection and severe outcomes with SARS-CoV-2 variants among those with history of SARS-CoV-2 infection

Subvariant/Outcome	Test Positive		Test Negative		Odds Ratio (95% CI)		VE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	Unadjusted	Adjusted ^b	Unadjusted	Adjusted ^b
BA.4/BA.5								
SARS-CoV-2 infection	91 (9.3%)	886 (90.7%)	735 (19.5%)	3043 (80.5%)	0.425 (0.338, 0.535)	0.482 (0.372, 0.625)	57.5% (46.5%, 66.2%)	51.8% (37.5%, 62.8%)
ED/UC encounters	23 (10.6%)	195 (89.4%)	803 (17.7%)	3734 (82.3%)	0.548 (0.354, 0.851)	0.402 (0.246, 0.656)	45.2% (14.9%, 64.6%)	59.8% (34.4%, 75.4%)
COVID-19 hospitalization ^{c,d}	1 (9.1%)	10 (90.9%)	825 (17.4%)	3919 (82.6%)	0.475 (0.061, 3.716)	0.140 (0.016, 1.195)	52.5% (-73.1%, 93.9%)	86.0% (-16.3%, 98.4%)
COVID-19 hospital death	0 (0.0%)	1 (100.0%)	826 (17.4%)	3928 (82.6%)	N/A	N/A	N/A	N/A
XBB								
SARS-CoV-2 infection	196 (38.7%)	311 (61.3%)	632 (37.2%)	1066 (62.8%)	1.063 (0.867, 1.304)	1.253 (0.972, 1.617)	-5.9% (-23.3%, 13.3%)	-20.2% (-38.1%, 2.8%)
ED/UC encounters ^c	72 (36.5%)	125 (63.5%)	756 (37.6%)	1252 (62.4%)	0.954 (0.704, 1.292)	0.787 (0.550, 1.128)	4.6% (-22.6%, 29.6%)	21.3% (-11.3%, 45.0%)
COVID-19 hospitalization ^{c,d,e}	5 (41.7%)	7 (58.3%)	823 (37.5%)	1370 (62.5%)	1.189 (0.376, 3.759)	0.342 (0.095, 1.233)	-15.9% (-73.4%, 62.4%)	65.8% (-18.9%, 90.5%)
COVID-19 hospital death	0	0	828 (37.6%)	1377 (62.4%)	N/A	N/A	N/A	N/A

BMI= body mass index, ED/UC = emergency department/urgent care, OR = odds ratio, VE = vaccine effectiveness, N/A = not applicable

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1 .

^b Unconditional logistic regression models adjusted for age, sex, race/ethnicity, month of specimen collection, time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, BMI, pregnancy, specimen type, and medical center area.

^c Medical center area dropped due to lack of model convergence.

^d BMI and specimen type dropped due to lack of model convergence.

^e History of SARS-CoV-2 molecular test, number of outpatient and virtual visits, and pregnancy dropped due to lack of model convergence.

Supplementary Table 11. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥2 monovalent mRNA vaccines against infection and severe outcomes with SARS-CoV-2 variants by time since vaccination, using SGTF data to assign unidentified subvariants

Subvariant/Time since vaccination	Test Positive		Test Negative		Odds Ratio (95% CI)		rVE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	≥2 doses monovalent mRNA vaccinated (%)	mRNA-1273 bivalent vaccinated (%)	≥2 doses monovalent mRNA vaccinated (%)	Unadjusted	Adjusted ^{b,c}	Unadjusted	Adjusted ^{b,c}
BA.4/BA.5								
SARS-CoV-2 infection	1375 (11.1%)	10957 (88.9%)	5678 (15.3%)	31318 (84.7%)	0.661 (0.618, 0.706)	0.590 (0.549, 0.634)	33.9% (29.4%, 38.2%)	41.0% (36.6%, 45.1%)
14-60 days	788 (6.7%)	10957 (93.3%)	3624 (10.4%)	31318 (89.6%)	0.621 (0.574, 0.673)	0.527 (0.483, 0.574)	37.9% (32.7%, 42.6%)	47.3% (42.6%, 51.7%)
61-120 days	535 (4.7%)	10957 (95.3%)	1878 (5.7%)	31318 (94.3%)	0.814 (0.738, 0.899)	0.665 (0.598, 0.741)	18.6% (10.1%, 26.2%)	33.5% (25.9%, 40.2%)
121-180 days	51 (0.5%)	10957 (99.5%)	175 (0.6%)	31318 (99.4%)	0.833 (0.609, 1.139)	0.721 (0.519, 1.001)	16.7% (-12.2%, 39.1%)	27.9% (-0.1%, 48.1%)
>180 days	1 (0.0%)	10957 (100.0%)	1 (0.0%)	31318 (100.0%)	2.858 (0.179, 45.70)	1.863 (0.109, 31.74)	-65.0% (-97.8%, 82.1%)	-46.3% (-96.8%, 89.1%)
ED/UC encounters	364 (11.9%)	2700 (88.1%)	1599 (17.4%)	7593 (82.6%)	0.602 (0.529, 0.686)	0.498 (0.429, 0.577)	39.8% (31.4%, 47.1%)	50.2% (42.3%, 57.1%)
14-60 days ^d	210 (7.2%)	2700 (92.8%)	984 (11.5%)	7593 (88.5%)	0.600 (0.514, 0.701)	0.525 (0.444, 0.621)	40.0% (29.9%, 48.6%)	47.5% (37.9%, 55.6%)
61-120 days ^d	136 (4.8%)	2700 (95.2%)	551 (6.8%)	7593 (93.2%)	0.694 (0.572, 0.842)	0.609 (0.494, 0.751)	30.6% (15.8%, 42.8%)	39.1% (24.9%, 50.6%)
121-180 days ^d	17 (0.6%)	2700 (99.4%)	64 (0.8%)	7593 (99.2%)	0.747 (0.437, 1.277)	0.699 (0.398, 1.226)	25.3% (-21.7%, 56.3%)	30.1% (-18.4%, 60.2%)
>180 days ^d	1 (0.0%)	2700 (100.0%)	0 (0.0%)	7593 (100.0%)	N/A	N/A	N/A	N/A
COVID-19 hospitalization ^d	28 (10.4%)	241 (89.6%)	208 (25.8%)	599 (74.2%)	0.307 (0.198, 0.478)	0.372 (0.222, 0.624)	69.3% (52.2%, 80.2%)	62.8% (37.6%, 77.8%)
14-60 days ^d	13 (5.1%)	241 (94.9%)	133 (18.2%)	599 (81.8%)	0.243 (0.135, 0.438)	0.318 (0.170, 0.597)	75.7% (56.2%, 86.5%)	68.2% (40.3%, 83.0%)
61-120 days ^d	14 (5.5%)	241 (94.5%)	70 (10.5%)	599 (89.5%)	0.497 (0.275, 0.899)	0.593 (0.301, 1.170)	50.3% (10.1%, 72.5%)	40.7% (-14.5%, 69.9%)
121-180 days ^d	0 (0.0%)	241 (100.0%)	5 (0.8%)	599 (99.2%)	N/A	N/A	N/A	N/A
>180 days ^d	1 (0.4%)	241 (99.6%)	0 (0.0%)	599 (100.0%)	N/A	N/A	N/A	N/A
COVID-19 hospital death ^{d,e}	2 (11.8%)	15 (88.2%)	13 (25.5%)	38 (74.5%)	0.358 (0.069, 1.869)	0.469 (0.035, 6.337)	64.2% (-46.5%, 93.1%)	53.1% (-84.2%, 96.5%)
XBB								
SARS-CoV-2 infection	1166 (21.2%)	4334 (78.8%)	3132 (19.0%)	13368 (81.0%)	1.160 (1.073, 1.255)	0.972 (0.891, 1.060)	-13.8% (-20.3%, -6.8%)	2.8% (-5.7%, 10.9%)
14-60 days	106 (2.4%)	4334 (97.6%)	442 (3.2%)	13368 (96.8%)	0.740 (0.597, 0.917)	0.587 (0.469, 0.736)	26.0% (8.3%, 40.3%)	41.3% (26.4%, 53.1%)
61-120 days	303 (6.5%)	4334 (93.5%)	984 (6.9%)	13368 (93.1%)	0.950 (0.831, 1.085)	0.771 (0.667, 0.890)	5.0% (-7.8%, 16.9%)	22.9% (11.0%, 33.3%)
121-180 days	401 (8.5%)	4334 (91.5%)	970 (6.8%)	13368 (93.2%)	1.275 (1.129, 1.440)	1.098 (0.963, 1.252)	-21.6% (-30.5%, -11.5%)	-9.0% (-20.1%, 3.7%)
>180 days	356 (7.6%)	4334 (92.4%)	736 (5.2%)	13368 (94.8%)	1.492 (1.309, 1.701)	1.273 (1.101, 1.472)	-33.0% (-41.2%, -23.6%)	-21.5% (-32.1%, -9.2%)
ED/UC encounters	408 (21.2%)	1513 (78.8%)	1255 (21.8%)	4508 (78.2%)	0.967 (0.849, 1.101)	0.764 (0.660, 0.886)	3.3% (-9.2%, 15.1%)	23.6% (11.4%, 34.0%)

14-60 days ^d	24 (1.6%)	1513 (98.4%)	176 (3.8%)	4508 (96.2%)	0.406 (0.264, 0.625)	0.310 (0.199, 0.484)	59.4% (37.5%, 73.6%)	69.0% (51.6%, 80.1%)
61-120 days ^d	107 (6.6%)	1513 (93.4%)	342 (7.1%)	4508 (92.9%)	0.932 (0.745, 1.167)	0.730 (0.573, 0.929)	6.8% (-14.3%, 25.5%)	27.0% (7.1%, 42.7%)
121-180 days ^d	146 (8.8%)	1513 (91.2%)	404 (8.2%)	4508 (91.8%)	1.077 (0.883, 1.313)	0.931 (0.753, 1.150)	-7.1% (-23.8%, 11.7%)	6.9% (-13.1%, 24.7%)
>180 days ^d	131 (8.0%)	1513 (92.0%)	333 (6.9%)	4508 (93.1%)	1.172 (0.950, 1.447)	0.983 (0.780, 1.240)	-14.7% (-30.9%, 5.0%)	1.7% (-19.3%, 22.0%)
COVID-19 hospitalization ^d	40 (18.9%)	172 (81.1%)	209 (32.9%)	427 (67.1%)	0.482 (0.329, 0.705)	0.401 (0.255, 0.630)	51.8% (29.5%, 67.1%)	59.9% (37.0%, 74.5%)
14-60 days ^d	2 (1.1%)	172 (98.9%)	27 (5.9%)	427 (94.1%)	0.184 (0.043, 0.782)	0.128 (0.027, 0.596)	81.6% (21.8%, 95.7%)	87.2% (40.4%, 97.3%)
61-120 days ^d	7 (3.9%)	172 (96.1%)	54 (11.2%)	427 (88.8%)	0.322 (0.144, 0.721)	0.236 (0.098, 0.568)	67.8% (27.9%, 85.6%)	76.4% (43.2%, 90.2%)
121-180 days ^d	14 (7.5%)	172 (92.5%)	72 (14.4%)	427 (85.6%)	0.483 (0.265, 0.879)	0.433 (0.224, 0.836)	51.7% (12.1%, 73.5%)	56.7% (16.4%, 77.6%)
>180 days ^d	17 (9.0%)	172 (91.0%)	56 (11.6%)	427 (88.4%)	0.754 (0.426, 1.334)	0.643 (0.336, 1.232)	24.6% (-25.0%, 57.4%)	35.7% (-18.8%, 66.4%)
COVID-19 hospital death ^{d,e,f}	4 (28.6%)	10 (71.4%)	17 (40.5%)	25 (59.5%)	0.602 (0.166, 2.174)	0.682 (0.076, 6.133)	39.8% (-54.0%, 83.4%)	31.8% (-83.7%, 92.4%)

BMI= body mass index, ED/UC = emergency department/urgent care, OR = odds ratio, rVE = relative vaccine effectiveness, SGTF = S gene target failure, N/A = not applicable

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1

^b Applied conditional logistic models conditioned on matched pairs for SARS-CoV-2 infection, ED/UC encounters, hospitalization and hospital death outcomes. Models for time since vaccination analyses are unconditional logistic models, adjusted for age, sex, race/ethnicity, and month of specimen collection, in addition to the covariates listed below.

^c Adjusted for days since last monovalent dose, time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, number of emergency department visits, BMI, Charlson comorbidity score, frailty index, pregnancy, medical center area, and number of monovalent doses prior to index date.

^d Medical center area dropped due to lack of model convergence.

^e BMI, Charlson comorbidity score, frailty index, and pregnancy dropped due to lack of model convergence.

^f Number of monovalent doses prior to index date dropped due to lack of model convergence.

Supplementary Table 12. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against infection and severe outcomes with SARS-CoV-2 variants by time since vaccination, using SGTF data to assign unidentified subvariants

Subvariant/Time since vaccination	Test Positive		Test Negative		Odds Ratio (95% CI)		VE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	Unadjusted	Adjusted ^{b,c}	Unadjusted	Adjusted ^{b,c}
BA.4/BA.5								
SARS-CoV-2 infection ^d	1376 (22.4%)	4769 (77.6%)	4430 (24.0%)	14005 (76.0%)	0.867 (0.795, 0.944)	0.852 (0.778, 0.933)	13.3% (5.6%, 20.5%)	14.8% (6.7%, 22.2%)
14-60 days ^d	789 (14.2%)	4769 (85.8%)	2811 (16.7%)	14005 (83.3%)	0.824 (0.757, 0.898)	0.761 (0.689, 0.841)	17.6% (10.2%, 24.3%)	23.9% (15.9%, 31.1%)
61-120 days ^d	535 (10.1%)	4769 (89.9%)	1456 (9.4%)	14005 (90.6%)	1.079 (0.972, 1.198)	0.981 (0.870, 1.107)	-7.3% (-16.5%, 2.8%)	1.9% (-9.6%, 13.0%)
121-180 days ^d	51 (1.1%)	4769 (98.9%)	161 (1.1%)	14005 (98.9%)	0.930 (0.678, 1.277)	0.969 (0.687, 1.366)	7.0% (-21.7%, 32.2%)	3.1% (-26.8%, 31.3%)
>180 days ^d	1 (0.0%)	4769 (100.0%)	2 (0.0%)	14005 (100.0%)	1.469 (0.133, 16.20)	1.339 (0.083, 21.51)	-31.9% (-93.8%, 86.7%)	-25.3% (-95.4%, 91.7%)
ED/UC encounters	365 (24.1%)	1152 (75.9%)	1260 (27.7%)	3291 (72.3%)	0.748 (0.634, 0.883)	0.528 (0.438, 0.637)	25.2% (11.7%, 36.6%)	47.2% (36.3%, 56.2%)
14-60 days	211 (15.5%)	1152 (84.5%)	784 (19.2%)	3291 (80.8%)	0.769 (0.651, 0.908)	0.505 (0.412, 0.620)	23.1% (9.2%, 34.9%)	49.5% (38.0%, 58.8%)
61-120 days	136 (10.6%)	1152 (89.4%)	426 (11.5%)	3291 (88.5%)	0.912 (0.743, 1.119)	0.604 (0.473, 0.771)	8.8% (-10.6%, 25.7%)	39.6% (22.9%, 52.7%)
121-180 days	17 (1.5%)	1152 (98.5%)	48 (1.4%)	3291 (98.6%)	1.012 (0.580, 1.766)	0.755 (0.399, 1.430)	-1.2% (-43.4%, 42.0%)	24.5% (-30.1%, 60.1%)
>180 days	1 (0.1%)	1152 (99.9%)	2 (0.1%)	3291 (99.9%)	1.429 (0.129, 15.77)	0.737 (0.039, 14.10)	-30.0% (-93.7%, 87.1%)	26.3% (-92.9%, 96.1%)
COVID-19 hospitalization ^d	28 (21.4%)	103 (78.6%)	189 (48.1%)	204 (51.9%)	0.212 (0.123, 0.364)	0.209 (0.110, 0.398)	78.8% (63.6%, 87.7%)	79.1% (60.2%, 89.0%)
14-60 days ^d	13 (11.2%)	103 (88.8%)	109 (34.8%)	204 (65.2%)	0.236 (0.127, 0.440)	0.234 (0.118, 0.466)	76.4% (56.0%, 87.3%)	76.6% (53.4%, 88.2%)
61-120 days ^d	14 (12.0%)	103 (88.0%)	74 (26.6%)	204 (73.4%)	0.375 (0.202, 0.695)	0.372 (0.187, 0.738)	62.5% (30.5%, 79.8%)	62.8% (26.2%, 81.3%)
121-180 days ^d	0 (0.0%)	103 (100.0%)	6 (2.9%)	204 (97.1%)	N/A	N/A	N/A	N/A
>180 days ^d	1 (1.0%)	103 (99.0%)	0 (0.0%)	204 (100.0%)	N/A	N/A	N/A	N/A
COVID-19 hospital death ^{d,e,f}	2 (20.0%)	8 (80.0%)	12 (40.0%)	18 (60.0%)	0.414 (0.082, 2.102)	0.409 (0.077, 2.168)	58.6% (-52.4%, 91.8%)	59.1% (-53.9%, 92.3%)
XBB								
SARS-CoV-2 infection ^d	1166 (48.3%)	1250 (51.7%)	2995 (41.3%)	4253 (58.7%)	1.516 (1.353, 1.699)	1.420 (1.258, 1.603)	-34.0% (-41.1%, -26.1%)	-29.6% (-37.6%, -20.5%)
14-60 days ^d	106 (7.8%)	1250 (92.2%)	414 (8.9%)	4253 (91.1%)	0.871 (0.697, 1.088)	0.837 (0.658, 1.066)	12.9% (-8.1%, 30.3%)	16.3% (-6.2%, 34.2%)
61-120 days ^d	303 (19.5%)	1250 (80.5%)	899 (17.4%)	4253 (82.6%)	1.147 (0.992, 1.325)	1.186 (1.004, 1.400)	-12.8% (-24.5%, 0.8%)	-15.7% (-28.6%, -0.4%)
121-180 days ^d	401 (24.3%)	1250 (75.7%)	948 (18.2%)	4253 (81.8%)	1.439 (1.260, 1.643)	1.588 (1.358, 1.858)	-30.5% (-39.2%, -20.7%)	-37.0% (-46.2%, -26.4%)

>180 days ^d	356 (22.2%)	1250 (77.8%)	734 (14.7%)	4253 (85.3%)	1.651 (1.433, 1.901)	1.990 (1.666, 2.376)	-39.4% (-47.4%, -30.2%)	-49.7% (-57.9%, -40.0%)
ED/UC encounters	408 (44.4%)	511 (55.6%)	1172 (42.5%)	1585 (57.5%)	1.123 (0.933, 1.352)	1.005 (0.821, 1.230)	-11.0% (-26.1%, 6.7%)	-0.5% (-18.7%, 17.9%)
14-60 days	24 (4.5%)	511 (95.5%)	154 (8.9%)	1585 (91.1%)	0.483 (0.311, 0.752)	0.454 (0.284, 0.726)	51.7% (24.8%, 68.9%)	54.6% (27.4%, 71.6%)
61-120 days	107 (17.3%)	511 (82.7%)	326 (17.1%)	1585 (82.9%)	1.018 (0.801, 1.294)	0.925 (0.705, 1.214)	-1.8% (-22.7%, 19.9%)	7.5% (-17.6%, 29.5%)
121-180 days	146 (22.2%)	511 (77.8%)	377 (19.2%)	1585 (80.8%)	1.201 (0.968, 1.490)	1.146 (0.886, 1.482)	-16.8% (-32.9%, 3.2%)	-12.7% (-32.5%, 11.4%)
>180 days	131 (20.4%)	511 (79.6%)	315 (16.6%)	1585 (83.4%)	1.290 (1.028, 1.618)	1.219 (0.927, 1.603)	-22.5% (-38.2%, -2.7%)	-18.0% (-37.6%, 7.3%)
COVID-19 hospitalization ^{d,e}	40 (42.1%)	55 (57.9%)	197 (69.1%)	88 (30.9%)	0.281 (0.167, 0.474)	0.259 (0.142, 0.471)	71.9% (52.6%, 83.3%)	74.1% (52.9%, 85.8%)
14-60 days ^{d,e}	2 (3.5%)	55 (96.5%)	37 (29.6%)	88 (70.4%)	0.086 (0.020, 0.373)	0.063 (0.013, 0.295)	91.4% (62.7%, 98.0%)	93.7% (70.5%, 98.7%)
61-120 days ^{d,e}	7 (11.3%)	55 (88.7%)	58 (39.7%)	88 (60.3%)	0.193 (0.082, 0.453)	0.143 (0.055, 0.373)	80.7% (54.7%, 91.8%)	85.7% (62.7%, 94.5%)
121-180 days ^{d,e}	14 (20.3%)	55 (79.7%)	55 (38.5%)	88 (61.5%)	0.407 (0.207, 0.801)	0.364 (0.167, 0.796)	59.3% (19.9%, 79.3%)	63.6% (20.4%, 83.3%)
>180 days ^{d,e}	17 (23.6%)	55 (76.4%)	47 (34.8%)	88 (65.2%)	0.579 (0.302, 1.107)	0.562 (0.261, 1.208)	42.1% (-9.7%, 69.8%)	43.8% (-17.2%, 73.9%)
COVID-19 hospital death ^{d,e,f}	4 (80.0%)	1 (20.0%)	13 (86.7%)	2 (13.3%)	0.577 (0.033, 10.25)	0.690 (0.035, 13.55)	42.3% (-90.2%, 96.7%)	31.0% (-92.6%, 96.5%)

BMI= body mass index, ED/UC = emergency department/urgent care, OR = odds ratio, VE = vaccine effectiveness, SGTF = S gene target failure, N/A = not applicable

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1 .

^b Applied conditional logistic models conditioned on matched pairs for SARS-CoV-2 infection, ED/UC encounters, hospitalization and hospital death outcomes. Models for time since vaccination analyses are unconditional logistic models, adjusted for age, sex, race/ethnicity, and month of specimen collection, in addition to the covariates listed below.

^c Adjusted for time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, BMI, pregnancy, specimen type, and medical center area.

^d Medical center area dropped due to lack of model convergence.

^e Specimen type and pregnancy dropped due to lack of model convergence.

^f BMI and time since history of SARS-CoV-2 infection dropped due to lack of model convergence.

Supplementary Table 13. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥ 2 monovalent mRNA vaccines against infection and severe outcomes with XBB.1.5 subvariant

Outcome	Test Positive		Test Negative		Odds Ratio (95% CI)		rVE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	≥ 2 doses monovalent mRNA vaccinated (%)	mRNA-1273 bivalent vaccinated (%)	≥ 2 doses monovalent mRNA vaccinated (%)	Unadjusted	Adjusted ^b	Unadjusted	Adjusted ^b
SARS-CoV-2 infection	533 (20.7%)	2045 (79.3%)	1575 (20.4%)	6159 (79.6%)	1.021 (0.910, 1.144)	0.827 (0.728, 0.939)	-2.0% (-12.6%, 9.0%)	17.3% (6.1%, 27.2%)
ED/UC encounters	230 (20.4%)	898 (79.6%)	784 (23.2%)	2600 (76.8%)	0.840 (0.708, 0.996)	0.692 (0.571, 0.839)	16.0% (0.4%, 29.2%)	30.8% (16.1%, 42.9%)
COVID-19 hospitalization ^c	25 (16.8%)	124 (83.2%)	143 (32.0%)	304 (68.0%)	0.432 (0.269, 0.695)	0.375 (0.211, 0.667)	56.8% (30.5%, 73.1%)	62.5% (33.3%, 78.9%)
COVID-19 hospital death ^{c,d}	1 (16.7%)	5 (83.3%)	6 (33.3%)	12 (66.7%)	0.361 (0.031, 4.214)	0.199 (0.007, 5.664)	63.9% (-76.3%, 96.9%)	80.1% (-82.3%, 99.3%)

BMI= body mass index, ED/UC = emergency department/urgent care, OR = odds ratio, rVE = relative vaccine effectiveness

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1 .

^b Applied conditional logistic models conditioned on matched pairs, additionally adjusted for days since last monovalent dose, time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, number of emergency department visits, BMI, Charlson comorbidity score, frailty index, pregnancy, medical center area, and number of monovalent doses prior to index date.

^c Medical center area dropped due to lack of model convergence.

^d Charlson comorbidity score, frailty index, BMI, pregnancy, number of outpatient and virtual visits, number of emergency department visits, and number of monovalent doses prior to index date dropped due to lack of model convergence.

Supplementary Table 14. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against infection and severe outcomes with XBB.1.5 subvariant

Outcome	Test Positive		Test Negative		Odds Ratio (95% CI)		VE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	Unadjusted	Adjusted ^b	Unadjusted	Adjusted ^b
SARS-CoV-2 infection ^c	533 (44.9%)	655 (55.1%)	1485 (41.7%)	2079 (58.3%)	1.205 (1.028, 1.413)	1.170 (0.988, 1.387)	-17.0% (-29.2%, -2.7%)	-14.6% (-27.9%, 1.2%)
ED/UC encounters ^c	230 (39.2%)	357 (60.8%)	738 (41.9%)	1023 (58.1%)	0.847 (0.672, 1.066)	0.837 (0.656, 1.069)	15.3% (-6.2%, 32.8%)	16.3% (-6.5%, 34.4%)
COVID-19 hospitalization ^{c,d}	25 (38.5%)	40 (61.5%)	138 (70.8%)	57 (29.2%)	0.233 (0.124, 0.437)	0.212 (0.100, 0.450)	76.7% (56.3%, 87.6%)	78.8% (55.0%, 90.0%)
COVID-19 hospital death	1 (50.0%)	1 (50.0%)	4 (66.7%)	2 (33.3%)	0.577 (0.033, 10.25)	N/A	42.3% (-90.2%, 96.7%)	N/A

BMI= body mass index, ED/UC = emergency department/urgent care, OR = odds ratio, VE = vaccine effectiveness, N/A = not applicable

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1

^b Applied conditional logistic models conditioned on matched pairs. Adjusted for time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, BMI, pregnancy, specimen type, and medical center area.

^c Medical center area dropped due to lack of model convergence.

^d Specimen type and pregnancy dropped due to lack of model convergence.

Supplementary Table 15. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. ≥2 monovalent mRNA vaccines against severe outcomes with SARS-CoV-2 variants among individuals without antiviral treatment

Subvariant/Time since vaccination	Test Positive		Test Negative		Odds Ratio (95% CI)		rVE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	≥2 doses monovalent mRNA vaccinated (%)	mRNA-1273 bivalent vaccinated (%)	≥2 doses monovalent mRNA vaccinated (%)	Unadjusted	Adjusted ^{b,c}	Unadjusted	Adjusted ^{b,c}
BA.4/BA.5								
COVID-19 hospitalization	23 (9.8%)	212 (90.2%)	184 (26.1%)	521 (73.9%)	0.296 (0.185, 0.473)	0.359 (0.207, 0.621)	70.4% (52.7%, 81.5%)	64.1% (37.9%, 79.3%)
14-60 days	11 (4.9%)	212 (95.1%)	120 (18.7%)	521 (81.3%)	0.225 (0.119, 0.426)	0.289 (0.146, 0.572)	77.5% (57.4%, 88.1%)	71.1% (42.8%, 85.4%)
61-120 days	11 (4.9%)	212 (95.1%)	62 (10.6%)	521 (89.4%)	0.436 (0.225, 0.844)	0.544 (0.255, 1.159)	56.4% (15.6%, 77.5%)	45.6% (-13.7%, 74.5%)
121-180 days	0 (0.0%)	212 (100.0%)	2 (0.4%)	521 (99.6%)	N/A	N/A	N/A	N/A
>180 days	1 (0.5%)	212 (99.5%)	0 (0.0%)	521 (100.0%)	N/A	N/A	N/A	N/A
COVID-19 hospital death ^{d,e}	2 (12.5%)	14 (87.5%)	13 (27.1%)	35 (72.9%)	0.358 (0.069, 1.869)	0.419 (0.031, 5.728)	64.2% (-46.5%, 93.1%)	58.1% (-82.5%, 96.9%)
XBB								
COVID-19 hospitalization ^d	37 (20.3%)	145 (79.7%)	173 (31.7%)	373 (68.3%)	0.562 (0.378, 0.837)	0.504 (0.311, 0.817)	43.8% (16.3%, 62.2%)	52.9% (22.9%, 71.2%)
14-60 days ^d	2 (1.4%)	145 (98.6%)	24 (6.0%)	373 (94.0%)	0.214 (0.050, 0.919)	0.142 (0.029, 0.691)	78.6% (8.1%, 95.0%)	85.8% (30.9%, 97.1%)
61-120 days ^d	6 (4.0%)	145 (96.0%)	46 (11.0%)	373 (89.0%)	0.336 (0.140, 0.803)	0.205 (0.078, 0.538)	66.4% (19.7%, 86.0%)	79.5% (46.2%, 92.2%)
121-180 days ^d	12 (7.6%)	145 (92.4%)	57 (13.3%)	373 (86.7%)	0.542 (0.282, 1.039)	0.495 (0.239, 1.026)	45.8% (-3.7%, 71.8%)	50.5% (-2.5%, 76.1%)
>180 days ^d	17 (10.5%)	145 (89.5%)	46 (11.0%)	373 (89.0%)	0.951 (0.528, 1.712)	0.978 (0.490, 1.952)	4.9% (-41.6%, 47.2%)	2.2% (-48.8%, 51.0%)
COVID-19 hospital death ^{d,e,f}	4 (30.8%)	9 (69.2%)	16 (41.0%)	23 (59.0%)	0.649 (0.174, 2.413)	0.695 (0.079, 6.142)	35.1% (-58.6%, 82.6%)	30.5% (-83.7%, 92.1%)

BMI= body mass index, OR = odds ratio, rVE = relative vaccine effectiveness, N/A = not applicable

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1

^b Applied conditional logistic models conditioned on matched pairs for hospitalization and hospital death outcomes. Models for time since vaccination analyses are unconditional logistic models, adjusted for age, sex, race/ethnicity, and month of specimen collection, in addition to the covariates listed below.

^c Adjusted for days since last monovalent dose, time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, number of emergency department visits, BMI, Charlson comorbidity score, frailty index, pregnancy, and number of monovalent doses prior to index date.

^d Pregnancy dropped due to lack of model convergence.

^e BMI, Charlson comorbidity score, and frailty index dropped due to lack of model convergence.

^f Number of monovalent doses prior to index date dropped due to lack of model convergence.

Supplementary Table 16. Vaccine effectiveness of mRNA-1273 bivalent vaccine vs. unvaccinated against severe outcomes with SARS-CoV-2 variants among individuals without antiviral treatment

Subvariant/Time since vaccination	Test Positive		Test Negative		Odds Ratio (95% CI)		VE (95% CI) ^a	
	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	mRNA-1273 bivalent vaccinated (%)	Unvaccinated (%)	Unadjusted	Adjusted ^{b,c}	Unadjusted	Adjusted ^{b,c}
BA.4/BA.5								
COVID-19 hospitalization	23 (21.9%)	82 (78.1%)	149 (47.3%)	166 (52.7%)	0.245 (0.137, 0.438)	0.231 (0.115, 0.461)	75.5% (56.2%, 86.3%)	76.9% (53.9%, 88.5%)
14-60 days	11 (11.8%)	82 (88.2%)	84 (33.6%)	166 (66.4%)	0.265 (0.134, 0.524)	0.254 (0.119, 0.542)	73.5% (47.6%, 86.6%)	74.6% (45.8%, 88.1%)
61-120 days	11 (11.8%)	82 (88.2%)	60 (26.5%)	166 (73.5%)	0.371 (0.185, 0.744)	0.376 (0.175, 0.808)	62.9% (25.6%, 81.5%)	62.4% (19.2%, 82.5%)
121-180 days	0 (0.0%)	82 (100.0%)	5 (2.9%)	166 (97.1%)	N/A	N/A	N/A	N/A
>180 days	1 (1.2%)	82 (98.8%)	0 (0.0%)	166 (100.0%)	N/A	N/A	N/A	N/A
COVID-19 hospital death ^{d,e}	2 (22.2%)	7 (77.8%)	10 (37.0%)	17 (63.0%)	0.518 (0.097, 2.755)	0.541 (0.099, 2.947)	48.2% (-63.7%, 90.3%)	45.9% (-66.1%, 90.1%)
XBB								
COVID-19 hospitalization ^d	37 (44.6%)	46 (55.4%)	175 (70.3%)	74 (29.7%)	0.309 (0.179, 0.532)	0.290 (0.156, 0.538)	69.1% (46.8%, 82.1%)	71.0% (46.2%, 84.4%)
14-60 days ^d	2 (4.2%)	46 (95.8%)	30 (28.8%)	74 (71.2%)	0.107 (0.024, 0.470)	0.073 (0.015, 0.355)	89.3% (53.0%, 97.6%)	92.7% (64.5%, 98.5%)
61-120 days ^d	6 (11.5%)	46 (88.5%)	55 (42.6%)	74 (57.4%)	0.175 (0.070, 0.440)	0.142 (0.052, 0.389)	82.5% (56.0%, 93.0%)	85.8% (61.1%, 94.8%)
121-180 days ^d	12 (20.7%)	46 (79.3%)	46 (38.3%)	74 (61.7%)	0.420 (0.201, 0.874)	0.378 (0.163, 0.877)	58.0% (12.6%, 79.9%)	62.2% (12.3%, 83.7%)
>180 days ^d	17 (27.0%)	46 (73.0%)	44 (37.3%)	74 (62.7%)	0.622 (0.318, 1.214)	0.581 (0.263, 1.282)	37.8% (-17.7%, 68.2%)	41.9% (-22.0%, 73.7%)
COVID-19 hospital death ^{d,e}	4 (80.0%)	1 (20.0%)	13 (86.7%)	2 (13.3%)	0.577 (0.033, 10.25)	0.690 (0.035, 13.55)	42.3% (-90.2%, 96.7%)	31.0% (-92.6%, 96.5%)

BMI= body mass index, OR = odds ratio, VE = vaccine effectiveness, N/A = not applicable

^a Calculated as $(1 - OR) \times 100$ when OR was ≤ 1 , and $([1/OR] - 1) \times 100$ when OR was > 1


^b Applied conditional logistic models conditioned on matched pairs for hospitalization and hospital death outcomes. Models for time since vaccination analyses are unconditional logistic models, adjusted for age, sex, race/ethnicity, and month of specimen collection, in addition to the covariates listed below.

^c Adjusted for time since history of SARS-CoV-2 infection, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, specimen type and BMI


^d Specimen type dropped due to lack of model convergence.

^e BMI and time since history of SARS-CoV-2 infection dropped due to lack of model convergence.

Supplementary Figure 1. Flow chart for Moderna bivalent vaccine test-negative design study population



Supplementary Figure 2. Distribution of SARS-CoV-2 variants by vaccination status



Supplementary Figure 3. Distribution of SARS-CoV-2 variants by month of specimen collection

